Cargando…

A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer

Background: Numerous lncRNAs have been shown to affect colon cancer (CC) progression, and tumor necroptosis is regulated by several of them. However, the prognostic value of necroptosis-related lncRNA in CC has rarely been reported. In this study, a necroptosis-related lncRNA prognostic model was co...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jian, Peng, Jiayu, Xiao, Wanying, Huang, Shujing, Cao, Yanqing, Wang, Ting, Wang, Xicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453677/
https://www.ncbi.nlm.nih.gov/pubmed/36092933
http://dx.doi.org/10.3389/fgene.2022.984696
_version_ 1784785191661731840
author Luo, Jian
Peng, Jiayu
Xiao, Wanying
Huang, Shujing
Cao, Yanqing
Wang, Ting
Wang, Xicheng
author_facet Luo, Jian
Peng, Jiayu
Xiao, Wanying
Huang, Shujing
Cao, Yanqing
Wang, Ting
Wang, Xicheng
author_sort Luo, Jian
collection PubMed
description Background: Numerous lncRNAs have been shown to affect colon cancer (CC) progression, and tumor necroptosis is regulated by several of them. However, the prognostic value of necroptosis-related lncRNA in CC has rarely been reported. In this study, a necroptosis-related lncRNA prognostic model was constructed, which can provide a reference for clinical diagnosis and treatment. Methods: The Cancer Genome Atlas (TCGA) database provided gene expression and lncRNA sequencing data for CC patients, and GSEA provided necroptosis gene data. Differentially expressed necroptosis-related lncRNAs related to prognosis were identified by differential expression analysis, Pearson correlation analysis, and least absolute shrinkage and selection operator (LASSO) regression. Based on the results of the multivariate COX regression analysis, a risk scoring model was constructed, A Kaplan-Meier analysis was performed to compare overall survival (OS) between low-risk and high-risk groups. A nomogram was then developed and validated based on the clinical data and risk scores of CC patients. In addition, Gene Set Enrichment Analysis (GSEA) and immune correlation analysis were conducted to explore the possible pathways and immune regulatory effects of these necroptosis-related lncRNAs. Results: In total, we identified 326 differentially expressed necroptosis-related lncRNAs in the TCGA database. Survival analysis showed that the OS of patients in the low-risk group was significantly better than that in the high-risk group (p < 0.05). Finally, 10 prognostic necroptosis-related lncRNAs were used to construct the nomogram. The composite nomogram prediction model evaluated and validated with good prediction performance (3-year AUC = 0.85, 5-years AUC = 0.82, C-index = 0.78). The GSEA and immune correlation analyses indicated that these lncRNAs may participate in multiple pathways involved in CC pathogenesis and progression. Conclusion: We established a novel necroptosis-related lncRNA CC prognosis prediction model, which can provide a reference for clinicians to formulate personalized treatment and review plans for CC patients. In addition, we also found that these necroptosis-related lncRNAs may affect the pathogenesis and progression of colon cancer through multiple pathways, including altering the activity of various immune cells.
format Online
Article
Text
id pubmed-9453677
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94536772022-09-09 A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer Luo, Jian Peng, Jiayu Xiao, Wanying Huang, Shujing Cao, Yanqing Wang, Ting Wang, Xicheng Front Genet Genetics Background: Numerous lncRNAs have been shown to affect colon cancer (CC) progression, and tumor necroptosis is regulated by several of them. However, the prognostic value of necroptosis-related lncRNA in CC has rarely been reported. In this study, a necroptosis-related lncRNA prognostic model was constructed, which can provide a reference for clinical diagnosis and treatment. Methods: The Cancer Genome Atlas (TCGA) database provided gene expression and lncRNA sequencing data for CC patients, and GSEA provided necroptosis gene data. Differentially expressed necroptosis-related lncRNAs related to prognosis were identified by differential expression analysis, Pearson correlation analysis, and least absolute shrinkage and selection operator (LASSO) regression. Based on the results of the multivariate COX regression analysis, a risk scoring model was constructed, A Kaplan-Meier analysis was performed to compare overall survival (OS) between low-risk and high-risk groups. A nomogram was then developed and validated based on the clinical data and risk scores of CC patients. In addition, Gene Set Enrichment Analysis (GSEA) and immune correlation analysis were conducted to explore the possible pathways and immune regulatory effects of these necroptosis-related lncRNAs. Results: In total, we identified 326 differentially expressed necroptosis-related lncRNAs in the TCGA database. Survival analysis showed that the OS of patients in the low-risk group was significantly better than that in the high-risk group (p < 0.05). Finally, 10 prognostic necroptosis-related lncRNAs were used to construct the nomogram. The composite nomogram prediction model evaluated and validated with good prediction performance (3-year AUC = 0.85, 5-years AUC = 0.82, C-index = 0.78). The GSEA and immune correlation analyses indicated that these lncRNAs may participate in multiple pathways involved in CC pathogenesis and progression. Conclusion: We established a novel necroptosis-related lncRNA CC prognosis prediction model, which can provide a reference for clinicians to formulate personalized treatment and review plans for CC patients. In addition, we also found that these necroptosis-related lncRNAs may affect the pathogenesis and progression of colon cancer through multiple pathways, including altering the activity of various immune cells. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9453677/ /pubmed/36092933 http://dx.doi.org/10.3389/fgene.2022.984696 Text en Copyright © 2022 Luo, Peng, Xiao, Huang, Cao, Wang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Luo, Jian
Peng, Jiayu
Xiao, Wanying
Huang, Shujing
Cao, Yanqing
Wang, Ting
Wang, Xicheng
A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer
title A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer
title_full A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer
title_fullStr A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer
title_full_unstemmed A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer
title_short A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer
title_sort novel necroptosis-related lncrna signature for predicting prognosis and immune response of colon cancer
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453677/
https://www.ncbi.nlm.nih.gov/pubmed/36092933
http://dx.doi.org/10.3389/fgene.2022.984696
work_keys_str_mv AT luojian anovelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT pengjiayu anovelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT xiaowanying anovelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT huangshujing anovelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT caoyanqing anovelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT wangting anovelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT wangxicheng anovelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT luojian novelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT pengjiayu novelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT xiaowanying novelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT huangshujing novelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT caoyanqing novelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT wangting novelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer
AT wangxicheng novelnecroptosisrelatedlncrnasignatureforpredictingprognosisandimmuneresponseofcoloncancer